Share
News
-
18 December 2006 /Prices and reimbursement
Consultation on recommended changes of the reimbursement status of lipid-lowering medicinal products
At several meetings, the Reimbursement Committee has discussed the reimbursement status of lipid-lowering medicinal products. In its recommendation of 7 September 2006 for the Danish Medicines Agency, the Committee suggests a change of reimbursement status for these medicinal products.
-
18 December 2006 /Prices and reimbursement
Reassessment of ATC group A, Alimentary tract and metabolism
At the beginning of 2007, the Danish Medicines Agency is going to begin the reassessment of ATC group A, alimentary tract and metabolism, starting with.
-
18 December 2006 /Prices and reimbursement
Reassessment of ATC-groups C01, C04 and C05
At its meeting on 19 September 2006, the Reimbursement Committee had its first discussion of the reimbursement status of the following ATC groups.
-
18 December 2006 /Prices and reimbursement
Reassessment of reimbursement status of the remaining subgroups of ATC group C
The Danish Medicines Agency previously notified companies and a number of scientific societies and patient organisations about which ATC groups and subgroups would be the first to be reassessed, cf. the fact box to the right.
-
18 December 2006 /Prices and reimbursement
Reassessment of reimbursement status
This summer, the Danish Medicines Agency will begin the periodic reassessment of reimbursement status of medicinal products. Over a 5-year period, the reimbursement status of all medicinal products will be reassessed to ensure that the medicinal products having been granted general reimbursement still meet the required criteria and that medicinal products which have not been granted general reimbursement do not meet the criteria.
-
18 December 2006 /Prices and reimbursement
Reassessment of reimbursement status of ATC-groups C01, C04 and C05
At its meetings on 19 September and 7 November 2006, the Reimbursement Committee discussed the reimbursement status of medicinal products in ATC-groups.
-
18 December 2006 /Prices and reimbursement
Reassessment of reimbursement status for medicinal products for hypertension
In March 2006, the Danish Medicines Agency contacted a number of scientific societies to clarify certain aspects of the treatment of hypertension in Denmark.
-
18 December 2006 /Prices and reimbursement
Reimbursement status of medicinal products aginst hypertension
On 6 March 2006, the Danish Medicines Agency wrote a letter to a number of scientific societies to make them clarify certain aspects of the treatment of hypertension in Denmark.
-
15 December 2006 /Side effects and trials
The European Commission publishes Volume 10 – clinical trials
The European Commission has gathered all relevant guidances, guidelines, legislaten, frequently asked questions, etc. concerning clinical trials in a Volume 10 in Eudralex.
-
08 November 2006 /News - miscellaneous
Illegal anti-impotence drug sold via coupon leaflets
The Danish Medicines Agency has become aware that the product Orexi+ from the Norwegian company Medisinsk Forlas AS is sold illegally via Danish coupon leaflets.
-
07 November 2006 /Side effects and trials
Steps towards improved consumer safety
Every year, mistakes and unintended incidents within the healthcare system, hereunder incorrect medication, cause patients and society great human and economic costs.
-
07 November 2006 /Product information
Warning against the Malaysian product Libidus with the substance vardenafil
The Canadian pharmaceutical authorities - Health Canada - have found a product containing the active substance vardenafil without this being indicated on the packets.
-
12 October 2006 /News - miscellaneous
The Danish Medicines Agency, the National Board of Health and the Danish Environmental Protection Agency makes a statement about tooth whitening products
Joint statement from the Danish Medicines Agency, the National Board of Health and the Danish Environmental Protection Agency about tooth whitening and tooth whitening products.
-
11 September 2006 /Prices and reimbursement
New executive order on the price list and delivery conditions
A new executive order on changes for "Bekendtgørelse for Medicinpriser og leveringsforhold" enters into force on 11 September 2006. The executive order is no. 875 of 17 August 2006.
-
11 August 2006 /Product information
Chinese products containing tadalafil, sildenafil and sibutramine
The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has found four products containing the active substances tadalafil, sildenafil or sibutramine without this appearing on the packets.
-
26 July 2006 /Product information
Kamagra tablets with sildenafil
The medicinal product Kamagra is sold on several internet pages. Kamagra tablets contain the active substance sildenafi, which is normally used for treatment of erectile dysfunction.
-
29 May 2006 /Side effects and trials
Investigation of the safety of MRI contrast medium Omniscan®
It has come to the attention of the Danish Medicines Agency that over a four year period 20 patients in Denmark and 5 patients in Austria have developed a very rare disease called 'Nephrogenic Fibrosing Dermopathy' or 'Nephrogenic Systemic Fibrosis' after the administration of Omniscan®.
-
24 April 2006 /Prices and reimbursement
Letter to scientific societies on treatment of hypertension
As part of the reassessment concerning medicinal products' reimbursement status, the Danish Medicines Agency has begun looking at reimbursement status of medicinal products for hypertension.
-
24 April 2006 /Prices and reimbursement
Reassessment of subgroups in ATC group C
The Danish Medicines Agency is just beginning to reassess the subgroups in ATC group C, medicinal products for the cardiovascular system, and for the first three months of 2006 the agency expects to be working with the following six subgroups.
-
21 April 2006 /Retail and online sale
Warning: Illegal copy of the medicinal product Cialis® sold on the internet
An illegal copy of the medicinal product Cialis® is sold on several websites under the name 'Sialis'. The illegal copy is either sold as 'Sialis' or as 'generic Cialis'
